Subtype
Malignant Female Reproductive System Neoplasm
CI-CAN-00003157Explore in graph →
1,464 active trials11 approved drugs128 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003157Explore in graph →
Clinical trials
6,254 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (740)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00587964 | Phase II Trial of Stereotactic Radiosurgery Boost Following Surgical Resection for Brain Metastases | completed | Phase 2 | 51 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 22, 2016 | clinicaltrials |
| NCT00216112 | Imatinib Mesylate in Combination With Docetaxel for Advanced, Platinum-Refractory Ovarian Cancer | completed | Phase 2 | 23 | Daniela Matei, MDOTHER | 1 | Feb 19, 2016 | clinicaltrials |
| NCT01426880 | Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer(GeparSixto) | completed | Phase 2 / Phase 3 | 595 | GBG Forschungs GmbHOTHER | 1 | Feb 15, 2016 | clinicaltrials |
| NCT00284427 | Safety of Antioxidants During GYN Cancer Care | completed | Phase 2 | 25 | Jeanne Drisko, MD, CNS, FACNOTHER | 0 | Feb 10, 2016 | clinicaltrials |
| NCT01238770 | Phase I/II Study of Pazopanib and Cyclophosphamide in Patients With Platinum-resistant Recurrent Ovarian Cancer | completed | Phase 1 / Phase 2 | 10 | Priv.-Doz. Dr. med. Joachim RomOTHER | 1 | Feb 10, 2016 | clinicaltrials |
| NCT01637532 | Feasibility of the Combination of Chemotherapy (Carbo/Caelyx or Carbo/Doxorubicin) With Tocilizumab (mAb IL-6R) and Peg-Intron in Patients With Recurrent Ovarian Cancer(PITCH) | completed | Phase 1 / Phase 2 | 21 | Leiden University Medical CenterOTHER | 1 | Jan 26, 2016 | clinicaltrials |
| NCT00474994 | Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas | completed | Phase 2 | 53 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 20, 2016 | clinicaltrials |
| NCT00588237 | Intravenous and Intraperitoneal Paclitaxel, Intraperitoneal Cisplatin, and Intravenous Bevacizumab for the Initial Treatment of Optimal Stage II or III Ovarian, Primary Peritoneal, and Fallopian Tube Cancer | completed | Phase 2 | 42 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 20, 2016 | clinicaltrials |
| NCT00401674 | MITO-5: Weekly Carboplatin and Paclitaxel as First Line Chemotherapy for Elderly Patients With Ovarian Cancer(MITO-5) | completed | Phase 2 | 26 | National Cancer Institute, NaplesOTHER | 1 | Jan 14, 2016 | clinicaltrials |
| NCT00403429 | MITO-6: Capecitabine in Platinum Resistant Ovarian Cancer | completed | Phase 2 | 36 | National Cancer Institute, NaplesOTHER | 1 | Jan 14, 2016 | clinicaltrials |
| NCT00008138 | S0009 Combination Chemo and Surgery in Stage III or Stage IV Ovarian Cancer(S0009) | completed | Phase 2 | 62 | SWOG Cancer Research NetworkNETWORK | 0 | Jan 8, 2016 | clinicaltrials |
| NCT01986725 | The Impact of the "WOMAN-PRO II Program" on Patients With Vulvar Neoplasia to Minimize Post-surgical Symptom Prevalence(WOMAN-PROII) | completed | Phase 2 | 45 | St.Gallen University of Applied SciencesOTHER | 1 | Jan 7, 2016 | clinicaltrials |
| NCT01356823 | Dose-Ranging Study of Recombinant Human Papillomavirus Virus 16/18 Bivalent Vaccine | completed | Phase 2 | 1,600 | Xiamen UniversityOTHER | 1 | Jan 5, 2016 | clinicaltrials |
| NCT00031954 | Combination Chemotherapy in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer | completed | Phase 2 | 105 | AGO Study GroupOTHER | 1 | Dec 23, 2015 | clinicaltrials |
| NCT00390234 | Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma | completed | Phase 2 | 63 | National Cancer Institute (NCI)NIH | 2 | Dec 7, 2015 | clinicaltrials |
| NCT00059787 | Erlotinib Plus Carboplatin and Paclitaxel in Ovarian Carcinoma | completed | Phase 2 | 56 | National Cancer Institute (NCI)NIH | 1 | Dec 1, 2015 | clinicaltrials |
| NCT00520598 | Broad Spectrum HPV (Human Papillomavirus) Vaccine in 16 to 26 Year Old Women (V505-001) | completed | Phase 2 | 511 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Nov 26, 2015 | clinicaltrials |
| NCT00024258 | Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid Tumors | completed | Phase 2 | 22 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 25, 2015 | clinicaltrials |
| NCT01091259 | Irinotecan and Bevacizumab for Recurrent Ovarian Cancer | completed | Phase 2 | 29 | NYU Langone HealthOTHER | 1 | Nov 24, 2015 | clinicaltrials |
| NCT00238121 | Sorafenib in Treating Patients With Advanced or Recurrent Uterine Cancer | completed | Phase 2 | 56 | National Cancer Institute (NCI)NIH | 2 | Nov 20, 2015 | clinicaltrials |
| NCT00057863 | Oxaliplatin and Paclitaxel in Treating Patients With Locally Recurrent or Metastatic Cervical Cancer | completed | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | Nov 17, 2015 | clinicaltrials |
| NCT00275028 | AZD2171 in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer | completed | Phase 2 | 47 | National Cancer Institute (NCI)NIH | 1 | Nov 9, 2015 | clinicaltrials |
| NCT00453310 | Sunitinib in Treating Patients With Metastatic Germ Cell Tumors That Have Relapsed or Not Responded to Treatment | completed | Phase 2 | 10 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Oct 27, 2015 | clinicaltrials |
| NCT02309658 | Neoadjuvant Chemotherapy in Locally Advanced Cervical Cancer Patients | completed | Phase 2 | 50 | Professor Fernando Figueira Integral Medicine InstituteOTHER | 1 | Oct 16, 2015 | clinicaltrials |
| NCT00703196 | Folic Acid Clinical Trial for the Prevention of Cervical Cancer | completed | Phase 2 | 368 | University of Alabama at BirminghamOTHER | 1 | Oct 8, 2015 | clinicaltrials |
| NCT01026792 | Temsirolimus in Treating Patients With Cervical Cancer That Is Recurrent, Locally Advanced, Metastatic, or Cannot Be Removed By Surgery | completed | Phase 2 | 38 | National Cancer Institute (NCI)NIH | 1 | Sep 10, 2015 | clinicaltrials |
| NCT00318370 | Effectiveness of MORAb-003 in Women With Ovarian Cancer Who Have Relapsed After Platinum-Based Chemotherapy | completed | Phase 2 | 58 | MorphotekINDUSTRY | 2 | Sep 9, 2015 | clinicaltrials |
| NCT00945139 | Study of Bevacizumab/Doxil in Treatment of Platinum-Resistant/Refractory Ovarian Cancer (CA) | completed | Phase 2 | 46 | New Mexico Cancer Research AllianceOTHER | 1 | Jul 31, 2015 | clinicaltrials |
| NCT00421889 | A Study of Belinostat + Carboplatin or Paclitaxel or Both in Patients With Ovarian Cancer in Need of Relapse Treatment | completed | Phase 1 / Phase 2 | 80 | Valerio TherapeuticsINDUSTRY | 3 | Jul 28, 2015 | clinicaltrials |
| NCT00100841 | Phase II Trial of FOLFOX6, Bevacizumab and Cetuximab in Patients With Colorectal Cancer | completed | Phase 2 | 66 | National Cancer Institute (NCI)NIH | 1 | Jul 27, 2015 | clinicaltrials |
| NCT00510250 | A Phase I/II Study of Cisplatin and Radiation in Combination With Sorafenib in Cervical Cancer | completed | Phase 1 / Phase 2 | 13 | University Health Network, TorontoOTHER | 1 | Jul 27, 2015 | clinicaltrials |
| NCT00072267 | UCN-01 and Topotecan in Treating Patients With Recurrent, Persistent, or Progressive Advanced Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer | completed | Phase 2 | — | University Health Network, TorontoOTHER | 1 | Jul 23, 2015 | clinicaltrials |
| NCT00739830 | Clinical Trial of Ridaforolimus Compared to Progestin or Chemotherapy for Advanced Endometrial Carcinoma (MK-8669-007 AM6) | completed | Phase 2 | 130 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jul 1, 2015 | clinicaltrials |
| NCT00096993 | A Study to Evaluate rhuMab 2C4 and Gemcitabine in Subjects With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | completed | Phase 2 | 131 | Genentech, Inc.INDUSTRY | 1 | Jun 10, 2015 | clinicaltrials |
| NCT01690598 | Veliparib and Topotecan for Relapsed Ovarian Cancer With Negative or Unknown BRCA Status | completed | Phase 1 / Phase 2 | 22 | Vejle HospitalOTHER | 1 | Jun 10, 2015 | clinicaltrials |
| NCT00260039 | Broad Spectrum HPV Vaccine Dose Ranging Study (V502-001) | completed | Phase 2 | 680 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jun 8, 2015 | clinicaltrials |
| NCT00551187 | A Study to Evaluate Tolerability and Immunogenicity of V504 Administered Concomitantly With GARDASIL (V504-001)(COMPLETED) | completed | Phase 2 | 620 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jun 8, 2015 | clinicaltrials |
| NCT00217633 | Pelvic Exenteration in Treating Patients With Recurrent Cervical Cancer | completed | Phase 2 | 38 | Gynecologic Oncology GroupNETWORK | 2 | May 29, 2015 | clinicaltrials |
| NCT01379534 | A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer | completed | Phase 2 | 53 | Novartis PharmaceuticalsINDUSTRY | 7 | May 20, 2015 | clinicaltrials |
| NCT00343044 | Ph II Study of Wkly Topotecan + Bevacizumab in Plat. Resistant/Recurrent Gyn Cancers | completed | Phase 2 | 40 | Benaroya Research InstituteOTHER | 1 | May 15, 2015 | clinicaltrials |
| NCT00072566 | Bevacizumab and Low-Dose Cyclophosphamide in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer | completed | Phase 2 | 70 | National Cancer Institute (NCI)NIH | 1 | May 12, 2015 | clinicaltrials |
| NCT00430781 | Pazopanib Plus Lapatinib Compared to Lapatinib Alone and Pazopanib Alone In Subjects With Metastatic Cervical Cancer | completed | Phase 2 | 228 | GlaxoSmithKlineINDUSTRY | 13 | May 8, 2015 | clinicaltrials |
| NCT00303823 | Green Tea Extract in Preventing Cervical Cancer in Patients With Human Papillomavirus and Low-Grade Cervical Intraepithelial Neoplasia | completed | Phase 2 | 98 | National Cancer Institute (NCI)NIH | 1 | May 5, 2015 | clinicaltrials |
| NCT01196741 | Saracatinib and Paclitaxel in Platinum-resistant Ovarian Cancer(SaPPrOC) | completed | Phase 2 / Phase 3 | 107 | University College, LondonOTHER | 1 | May 5, 2015 | clinicaltrials |
| NCT00039585 | Imatinib Mesylate in Treating Patients With Refractory or Relapsed Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer, or Ovarian Low Malignant Potential Tumor | completed | Phase 2 | — | National Cancer Institute (NCI)NIH | 1 | Apr 30, 2015 | clinicaltrials |
| NCT00267696 | Study of Gemcitabine/Carboplatin/Bevacizumab to Treat Ovarian, Fallopian Tube or Primary Peritoneal Cancer | completed | Phase 2 | 45 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Apr 30, 2015 | clinicaltrials |
| NCT00345540 | Efficacy of NOV-002 in Combination With Carboplatin in Chemotherapy-resistant Ovarian Cancer | completed | Phase 2 | 15 | Cellectar Biosciences, Inc.INDUSTRY | 1 | Mar 10, 2015 | clinicaltrials |
| NCT00090610 | Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer | completed | Phase 2 | 150 | Duke UniversityOTHER | 1 | Feb 25, 2015 | clinicaltrials |
| NCT00072176 | Temsirolimus in Treating Patients With Metastatic or Locally Advanced Recurrent Endometrial Cancer | completed | Phase 2 | 62 | National Cancer Institute (NCI)NIH | 1 | Feb 23, 2015 | clinicaltrials |
| NCT00122343 | AP23573 in Female Adult Patients With Recurrent or Persistent Endometrial Cancer (8669-019)(COMPLETED) | completed | Phase 2 | 45 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Feb 19, 2015 | clinicaltrials |
Data updated 23 days agoSource updated Feb 22, 2016source: clinicaltrials